Bristol Positive Topline Results in 2 Phase 3 Trials in Psoriatic Arthritis

 POETYK PsA-1 and POETYK PsA-2 trials met primary endpoint, with significantly greater proportion of Sotyktu-treated patients achieving ACR20 response compared with placebo at Week 16

Sotyktu was well-tolerated and demonstrated safety consistent with established profile

https://www.businesswire.com/news/home/20241220275848/en/